WASHINGTON (dpa-AFX) - Medical devices company St. Jude Medical Inc. (STJ) Wednesday announced CE Mark approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators or ICDs and cardiac resynchronization therapy defibrillators or CRT-Ds. The new portfolio is designed to lower the risk for lead abrasion and to ensure high voltage therapy delivery, said the company.
The Ellipse and SJM Assura family of devices feature the DynamicTx Over-Current Detection Algorithm, which automatically adjusts shocking configurations within the device to ensure the delivery of high-voltage therapy if an electrical short in one portion of the system were to occur, said the company. The next-generation Ellipse and SJM Assura portfolio of implantable defibrillators feature low friction coating on the device can, which has been demonstrated in testing to significantly reduce the friction between the device and leads, it added.
These technologies are expected to provide preventative and adaptive capabilities to address potential failures that can result in the inability to deliver high voltage therapy when needed, especially in systems using silicone-only insulated defibrillation leads, which are known to be at higher risk of abrasion.
The Ellipse and SJM Assura family of devices also feature expanded protection against inappropriate and unnecessary shocks with SecureSense RV Lead Noise Discrimination, an algorithm that expands St. Jude Medical ShockGuard Technology, said the company.
An ICD is an advanced implantable device that treats potentially lethal, abnormally fast heart rhythms, which often lead to sudden cardiac death. A CRT-D device resynchronizes the beating of the heart's lower chambers, which often beat out of sync in heart failure patients, and provides back up treatment for SCD, which is a risk factor associated with certain types of heart failure.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
